MA-TA
28.6.2022 15:15:13 CEST | Business Wire | Press release
TA, a leading global growth private equity firm with more than four decades of enterprise software investing experience, in partnership with ST6, an elite team of software operating executives, has formed a global software provider called Advantive. The new company offers Enterprise Resource Planning (ERP), Manufacturing Execution Systems (MES), and Statistical Process Control (SPC) software solutions for specialty manufacturers and wholesale distributors.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220628005803/en/
Advantive, which comes together through the combination of Advantzware, DDI System, Distribution One, InfinityQS, Kiwiplan and VIA, has more than 2,500 customers today across a number of industries including corrugated and packaging manufacturing, equipment and supply wholesale distributors, and automotive and other specialty manufacturers. Advantive will be headquartered in Tampa, Florida.
Benoit de la Tour, an accomplished executive in the ERP and Supply Chain software space, has been named the CEO of Advantive. “I'm thrilled to join Advantive as CEO, working hand-in-hand with TA and ST6 to deliver increased customer value,” said Benoit. “Advantive was formed with a simple purpose— to drive sustainable growth for specialty manufacturing and distribution companies. We’re in a unique position, alongside our customers, to make a real impact. With Advantive’s packaging, ecommerce and delivery solutions, spanning raw resources to valuable products, we’re transforming the manufacturing and distribution lifecycle.”
“We are excited to partner with Benoit and ST6 as we build upon the strength of Advantive’s constituent businesses to create an overall market leader in ERP, MES and SPC software,” said Hythem El-Nazer, a Managing Director at TA. “Advantive’s software solutions modernize and optimize every aspect of the manufacturing and distribution lifecycle, from enhanced plant production, supply chain optimization and ecommerce, to managing quality and compliance. Advantive is changing the way business is done, and we are excited to support the business as it grows.”
Mark Friedman, a longtime, experienced software operating executive and investor, is the Executive Chairman of Advantive. Friedman, currently a Managing Director at ST6, was previously the founder and CEO of Accruent, a leading software company that disrupted the multi-billion-dollar facilities management and lease administration software market. “Now more than ever, our customers need the ability to rapidly adapt to global supply chain challenges, and to gain a competitive advantage,” said Friedman. “By combining the strengths of Advantive’s constituent companies, and delivering deep, purpose-built software, we believe we are positioned to drive transformational outcomes for our customers.’
About Advantive
Advantive is a market leader in mission-critical software for specialty manufacturing and distribution companies, offering purpose-built ERP, MES and SPC software solutions that meet the unique needs of our customers. Serving over 2,500 customers and operating in 8 countries, Advantive’s software solutions streamline complex processes, optimize operations visibility and throughput, and drive improved quality, profitability and revenue growth. Deeply embedded into key end-to-end workflows, Advantive’s software uses automation, seamless integration and real-time data to streamline plant scheduling, order management, quality control, sales order forecasting and pricing, ecommerce and delivery – making the complex, simple.
About TA
TA is a leading global growth private equity firm. Focused on targeted sectors within five industries – technology, healthcare, financial services, consumer, and business services – the firm invests in profitable, growing companies with opportunities for sustained growth and has invested in more than 550 companies around the world. Investing as either a majority or minority investor, TA employs a long-term approach, utilizing its strategic resources to help management teams build lasting value in high quality growth companies. TA has raised $47.5 billion in capital since its founding in 1968. The firm’s more than 100 investment professionals are based in Boston, Menlo Park, London, Mumbai and Hong Kong. More information about TA can be found at www.ta.com .
About ST6
ST6 is an elite team of software operating executives that partner with private equity sponsors to transform software companies and accelerate value creation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220628005803/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aqemia and Sanofi Expand Their Research Collaboration17.7.2026 12:30:00 CEST | Press release
A new target nomination and a milestone payment mark the next step of the multi-year partnership first announced in December 2023 Aqemia, the drug invention company combining generative AI and quantum-inspired physics to invent small molecule drugs, today announced the expansion of its multi-year research collaboration with the global pharmaceutical company, Sanofi. The expansion is marked by the nomination of a new therapeutic target and an additional payment. The collaboration, first announced in December 2023, makes Aqemia eligible to receive up to a total of $140 million in upfront and milestone payments across programs. It spans the drug discovery journey from the identification of the very first hits to the selection of a development candidate. Aqemia leverages Qemi, its proprietary physics-based generative AI platform, to design novel molecules addressing Sanofi’s targets of choice, working in close collaboration with Sanofi scientific teams. Sanofi leads wet lab research, devel
China's ~$900B Live-Commerce Market Now Approaches US E-Commerce Scale17.7.2026 12:30:00 CEST | Press release
The consumer habits reshaping global retail were built in the East — and most Western shoppers haven't yet adopted them. NIQ report shows that brands still treating live, social, and quick commerce as "emerging" risk being left behind. The center of gravity in global retail has shifted East. The formats now driving the fastest growth in global retail (live shopping, social commerce, and delivery in minutes) were pioneered and scaled in Asia, and most Western consumers have yet to adopt them. According to NIQ (NYSE: NIQ), a leading consumer intelligence company, in its global report The Commerce Revolution: Where East Meets West, the gap between East and West is still vast. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717253489/en/ China´s USD 900bn live shopping boom now approaches the scale of the US E-commerce The scale is already substantial. China's live-commerce market alone was worth roughly $900 billion in 2025,
Ant International’s Alipay+ Connects Argentina's National QR Payment Scheme via PVS,Enabling for Cross-Border Digital Payment Nationwide at Millions of Merchants17.7.2026 12:17:00 CEST | Press release
Alipay+, a global digital payment gateway under Ant International, today announced that it will enable global travellers to make QR code payments at millions of merchants across Argentina through integration with the country's national QR payment scheme Transferencias 3.0, in partnership with PVS, a fintech company specialized in developing customized payment solutions in Latin America. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260717276406/en/ By connecting to Argentina's national QR payment scheme, Alipay+ now enables global travellers in the country to make convenient QR code payments at merchants nationwide. This service helps to enhance global travellers' travel experiences in Argentina, allowing them to pay seamlessly at restaurants, malls and tourist attractions. Using an Alipay+ partner payment app, they can now scan the national QR code displayed at all merchants to make cross-border payments across Argentina,
KATE Launches "KABUKE: Break Convention" Kabuki-Inspired International Campaign17.7.2026 09:00:00 CEST | Press release
Where “NO MORE RULES.” intersects with the Kabuku spirit. Inspired by Japanese aesthetics, KATE shares the value of shadow enhancing makeup and self‑expression with the world. Global cosmetics brand KATE launched “KABUKE: Break Convention,” a new international campaign drawing on elements of Kabuki, the traditional Japanese performing art. The campaign debuted on Wednesday, July 8, 2026. In this campaign, KATE’s shadow enhancing makeup—rooted in Japanese aesthetics—was paired with the Kabuki spirit inherited from traditional Kabuki theater to communicate the value of individuality and self‑expression through makeup on a global scale. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260708829427/en/ KATE international campaign “KABUKE: Break Convention” key visual. Dedicated website: https://www.kate-global.net/my/special/kate_kabuki/ Since its founding, KATE has championed the slogan “NO MORE RULES.,” offering makeup that defi
Meiji Seika Pharma: Results from the Global Phase III Trial (Integral-2) of Nacubactam, a Novel β-Lactamase Inhibitor, Highlighted in The Lancet Microbe’s Coverage of ESCMID Global Congress 202617.7.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, President and Representative Director: Toshiaki Nagasato) today announced that results from the global Phase III trial (Integral-2) of nacubactam (Development Code: OP0595), a novel β-lactamase inhibitor, were highlighted in The Lancet Microbe’s coverage of ESCMID Global Congress 2026 (held in Munich, Germany). As highlighted in The Lancet Microbe’s coverage, the key findings presented by Meiji Seika Pharma at ESCMID Global Congress 2026 are as follows: The Integral-2 study (jRCT2031230076) is a global Phase III clinical trial that enrolled patients with complicated urinary tract infections, acute uncomplicated pyelonephritis, hospital-acquired bacterial pneumonia, ventilator-associated bacterial pneumonia, or complicated intra-abdominal infections caused by carbapenem-resistant Gram-negative bacteria (excluding Acinetobacter species). The study has achieved the prespecified study objectives. For the primary endpoint of overall treatme
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
